Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Neonc Technologies, Inc.
National Cancer Institute (NCI)
University of Nebraska
Eli Lilly and Company
ITM Solucin GmbH
National Cancer Institute (NCI)
University of Southern California
Massive Bio, Inc.
Eli Lilly and Company
National Cancer Institute (NCI)
RefleXion Medical
Eli Lilly and Company